miércoles, 12 de febrero de 2025

FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brentuximab-vedotin-lenalidomide-and-rituximab-relapsed-or-refractory-large-b-cell?utm_medium=email&utm_source=govdelivery

No hay comentarios:

Publicar un comentario